Comparative abuse liability of GHB and ethanol in humans.
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Gamma-hydroxybutyric acid (GHB; sodium oxybate) is approved for narcolepsy symptom treatment, and it is also abused. This study compared the participant-rated, observer-rated effects, motor/cognitive, physiological, and reinforcing effects of GHB and ethanol in participants with histories of sedative (including alcohol) abuse. Fourteen participants lived on a residential unit for ∼1 month. Sessions were conducted Monday through Friday. Measures were taken before and repeatedly up to 24 hours after drug administration. Participants were administered GHB (1, 2, 4, 6, 8, and 10 g/70 kg), ethanol (12, 24, 48, 72, 96, and 120 g/70 kg), or placebo in a double-blind, within-subjects design. For safety, GHB and ethanol were administered in an ascending dose sequence, with placebos and both drugs intermixed across sessions. The sequence for each drug was stopped if significant impairment or intolerable effects occurred. Only 9 and 10 participants received the full dose range for GHB and ethanol, respectively. The highest doses of GHB and ethanol showed onset within 30 minutes, with peak effects at 60 minutes. GHB effects dissipated between 4 and 6 hours, whereas ethanol effects dissipated between 6 and 8 hours. Dose-related effects were observed for both drugs on a variety of measures assessing sedative drug effects, abuse liability, performance impairment, and physiological effects. Within-session measures of abuse liability were similar between the two drugs. However, postsession measures of abuse liability, including a direct preference test between the highest tolerated doses of each drug, suggested somewhat greater abuse liability for GHB, most likely as a result of the delayed aversive ethanol effects (e.g., headache).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gamma hydroxybutyric acid (ghb) for the treatment of alcohol dependence: A review
Caputo, F., Vignoli, T., Maremmani, I., Bernardi, M., & Zoli, G. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6061917 · Cited by 73
Cited by
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
“Approval of drugs with REMS anticipates the likelihood that emerging clinical Please cite this article in press as: Johnson, M.W., et al., The abuse potent Substances Act, Neuropharmacology (2018), https://doi.org/10.1016/j.neu experience, further research, and the relatively high level of oversight and data collectio…”
InfluentialSelf-citationSetnik, B., McDonnell, M., Mills, C., Scart-Grès, C., Robert, P., Dayno, J. M., & Schwartz, J.-C. (2020) · Sleep · doi:10.1093/sleep/zsz252 · Cited by 189
“In a study of nondependent, recreational users of both ethanol and other sedative-hypnotics, drug liking was significantly greater for sodium oxybate (at doses up to 10 g/70 kg) compared with placebo; drug liking for sodium oxybate was similar to that for alcohol, whereas willingness to take the drug again was signifi…”
BackgroundMechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Guiraud, J., Addolorato, G., Aubin, H.-J., Batel, P., de Bejczy, A., Caputo, F., Goudriaan, A. E., Gual, A., Lesch, O., Maremmani, I., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.003 · Cited by 20
Metadata
- Authors
- Johnson, M. W., & Griffiths, R. R.
- Venue
- Experimental and Clinical Psychopharmacology
- Published
- 2013-04
- Volume
- 21
- Issue
- 2
- Pages
- 112-123
- ISSN
- 1064-1297 (ISSN-L)
- 1936-2293
- OpenAlex
- W2321131279
- Cited by
- 26
- References
- 1
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.